kalvista - Search News

News

KalVista's breakthrough drug wins FDA approval

Reuters on MSN · 21h

US FDA approves KalVista's oral swelling disorder drug, shares rise

KalVista Pharmaceuticals said on Monday the U.S. Food and Drug Administration has approved its drug, the first on-demand oral treatment for a type of hereditary swelling disorder, sending its shares up more than 18%.

The Business Journals · 21h

KalVista's breakthrough drug wins FDA approval after delay

KalVista's journey to FDA approval wasn't smooth sailing, with an unexpected delay and alleged behind-the-scenes drama at the regulatory agency.

Business Wire · 1d

KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved EKTERLY® (sebetralstat), a novel

Kalkine Media19h

FDA Clears First Oral HAE Treatment S&P 500 Focus Turns to KalVista

KalVista Pharmaceuticals Inc, a clinical-stage pharmaceutical company listed on the S&P 500, has achieved a significant ...

21h

Orsini Selected as Specialty Pharmacy Partner for KalVista's EKTERLY® (sebetralstat)

Orsini, a leader in rare disease pharmacy solutions, has been chosen by KalVista Pharmaceuticals as a specialty pharmacy ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results